Adropin is a peptide hormone that was first identified in 2008 and was first thought to have a significant role in the balance of fatty acids and glucose in peripheral tissues. We look at the relationship between adropin and diabetes individuals' ischemic heart disease. The objective of the study is to evaluate the serum adropin level as a potential indicator of ischemic heart disease in people with type 2 diabetes mellitus. The 90 participants in this case-control study were split into three groups: Group (I) consisted of 30 T2DM patients with ischemic heart disease Group (II) consisted of 30 T2DM patients without ischaemic heart disease Group (III) consisted of 30 healthy persons as the control group. HbA1c, lipid profile (cholesterol, triglycerides, LDL-C, HDL), HOMA IR serum creatinine, AST, ALT, and serum adropin were also evaluated. Fasting plasma glucose, 2h postprandial plasma glucose, Carotid artery intimal thickness using ultrasound, and Carotid artery intimal thickness were also measured. Patients with diabetes who did not have ischemic heart disease had a statistically significant rise in serum Adropin hormone (p value 0.001), with values of (26.867 10.037) ng/L and (87.500 40.509) ng/L, respectively. Additionally, there was a bad correlation between serum adropin and CIMT and fasting insulin. Assessment of serum adropin levels may serve as a risk indicator for the emergence of ischemic heart disease in people with type 2 diabetes mellitus.